Skip to main content

Novartis AG (NVS) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $146.69 (-0.78%)

Consensus Target
$127.00
Upside
-3.9%
Analysts
2
Rating
Buy(2.50)

Price Target Range

Low $112.00Consensus $127.00High $143.00
▲ Current $146.69

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

NVS vs Sector & Market

MetricNVSHealthcare AvgLarge Cap Avg
Analyst Rating2.502.242.41
Analyst Count2818
Target Upside-3.9%+1150.3%+14.9%
P/E Ratio19.866.8531.19

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$13.97B$14.14B$14.36B4
2026-09-30$14.15B$14.52B$14.77B2
2026-12-31$14.39B$14.77B$15.02B3
2027-03-31$13.46B$13.82B$14.05B3
2027-06-30$14.03B$14.40B$14.64B2
2027-09-30$14.26B$14.63B$14.88B2
2027-12-31$14.37B$14.76B$15.00B3

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$2.10$2.19$2.282
2026-09-30$2.19$2.26$2.311
2026-12-31$2.11$2.19$2.231
2027-03-31$2.17$2.25$2.301
2027-06-30$2.29$2.37$2.421
2027-09-30$2.33$2.41$2.461
2027-12-31$2.34$2.42$2.471

Frequently Asked Questions

What is the analyst consensus for NVS?

The consensus among 2 analysts covering Novartis AG (NVS) is Buy with an average price target of $127.00.

What is the highest price target for NVS?

The highest analyst price target for NVS is $143.00.

What is the lowest price target for NVS?

The lowest analyst price target for NVS is $112.00.

How many analysts cover NVS?

2 analysts have issued ratings for Novartis AG in the past 12 months.

Is NVS a buy or sell right now?

Based on 2 analyst ratings, NVS has a consensus rating of Buy (2.50/5) with a -3.9% upside to the consensus target of $127.00.

What are the earnings estimates for NVS?

Analysts estimate NVS will report EPS of $2.19 for the period ending 2026-06-30, with revenue estimated at $14.14B.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.